Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 3/20 | 0.31 |
| ▸ | MMP13 | P45452 | 3/20 | 0.30 |
| ▸ | MMP10 | P09238 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904915 | 0.89 | CYP2C9 (0.38) | KCNH2CYP2C9MMP13MMP10MMP8 | |
| SCHEMBL9942882 | 0.88 | RORC (0.32) | KCNH2P2RX7CYP2C9RORCMMP13 | |
| SCHEMBL9942869 | 0.84 | MMP13 (0.35) | KCNH2CYP2C9MMP13MMP10MMP8 | |
| SCHEMBL9942884 | 0.84 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL9942971 | 0.84 | KCNH2 (0.35) | KCNH2CYP2C9MMP13MMP10MMP8 | |
| SCHEMBL9905172 | 0.83 | KCNH2 (0.35) | KCNH2CYP2C9MMP13MMP10MMP8 | |
| SCHEMBL9901046 | 0.82 | CYP2C9 (0.37) | KCNH2CYP2C9MMP13MMP10MMP8 | |
| SCHEMBL9904934 | 0.81 | MMP13 (0.36) | KCNH2CYP2C9MMP13MMP10MMP8 | |
| SCHEMBL9942907 | 0.81 | CYP2C9 (0.46) | KCNH2CYP2C9 | |
| SCHEMBL9943018 | 0.78 | CYP2C9 (0.41) | KCNH2CYP2C9MMP13MMP10MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835411-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835411-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| WO-2012078834-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309698-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | KCNH2 3969/4885P2RX7 3911/4885CYP2C9 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.